Health Care Supplies

WEIGAO GROUP

Weigao Medical Polymers Reports 5.3% YoY Revenue Growth for Q1 2026

Morgan Stanley Downgrades Weigao Group's Profit Forecast and Target Price

Weigao Group Repurchased 120,000 Shares for HKD412,800

Wego Shares Establishes Fund to Boost Internationalization and Technological Innovation

Shandong Weigao Group Medical Polymers Holds 2026 Annual General Meeting

Weigao Group repurchased 540,000 shares for HKD 1.9098 million

Weigao Group repurchased 180,000 shares

Weigao Group repurchased 340,000 shares

Weigao Group repurchased 320,000 shares for HKD 1.1644 million

Weigao Group repurchased 280,000 shares

Citi Downgrades Pingpu's Target Price But Maintains Buy Rating

Weigao Group repurchased 500,000 shares at a cost of HKD 1.902 million

Goldman Sachs Downgrades Weigao Group's Earnings Forecast and Target Price

WEIGAO GROUP released FY2025 9 Months earnings on March 27 (BJT), actual revenue HKD 10.88 B, actual EPS HKD 0.3092

WEIGAO GROUP released FY2025 Q3 earnings on March 27 (BJT), actual revenue HKD 3.687 B, actual EPS HKD 0.0728

WEIGAO GROUP released FY2025 earnings on March 27 After-Market (BJT), actual revenue HKD 14.63 B (forecast HKD 15.08 B), actual EPS HKD 0.3825 (forecast HKD 0.4907)

WEIGAO GROUP released FY2025 Q4 earnings on March 27 After-Market (BJT), actual revenue HKD 3.75 B, actual EPS HKD 0.0722

WEIGAO GROUP to release FY2025 earnings on March 27 After-Market (BJT), forecast revenue HKD 15.43 B, EPS HKD 0.4992

Weigao Group repurchased 60,000 shares for HKD 314,200

Shandong Weigao Medical Polymers repurchased 60,000 H shares

HINSANG GROUP

RIVERINE CHINA

PASHUN INT RTS

BRAINAURORA-B

SOFTMEDX

GOLDENPOWER

ZHONGKE GROUP

VISION SYNERGY

GEMILANG INTL

GHPC

Ordinary dividend (cash)

Ex Date: 2026.06.02, Cash dividend 0.0679 HKD

01066

M Stanley has revised its revenue forecasts for WEIGAO GROUP, increasing them by 4% annually for 2026 to 2028, while lowering EPS forecasts by 14.7%, 13.8%, and 14.2% respectively. The target price has been cut from HKD6 to HKD5.2, maintaining an Equalweight rating. The adjustments reflect ongoing pricing pressures and the impact of volume-based procurement. WEIGAO GROUP has a diversified presence in medical technology in China but faces challenges from price cuts and below-average sales volume.

AASTOCKS News

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Cuts WEIGAO GROUP  TP to HKD5.2, Lowers EPS Forecasts

Shandong Weigao Group Medical Polymer Co has established a Korea-focused private fund through its subsidiary, Wego Healthcare Fund, targeting small and mid-sized enterprises specializing in open innovation and cross-border expansion. The fund is set at KRW52.97 billion, with Wego Healthcare committing KRW15.89 billion. This transaction is classified as connected under Hong Kong listing rules, requiring reporting but not independent shareholder approval. The latest analyst rating for Shandong Weigao stock is a Hold with a price target of HK$4.00.

Tip Ranks

Shandong Weigao Sets Up Korea-Focused Fund in Connected Deal

Shandong Weigao Medical Polymer Co. (OTCMKTS:SHWGF) experienced a significant increase in short interest, rising 745.8% to 4,451,429 shares by April 15th. Currently, 0.1% of the company's stock is sold short, with a short-interest ratio of 816.0 days based on an average daily trading volume of 5,455 shares. The stock price remained flat at $0.45, with a 12-month low of $0.45 and a high of $0.73. Analysts currently rate the stock as a Hold, but suggest other stocks may be better investment options.

Market Beat

Shandong Weigao Medical Polymer Co. (OTCMKTS:SHWGF) Sees Large Increase in Short Interest

159883

159898

562600

Shandong Weigao Group Medical Polymer Co has received approval from the China Securities Regulatory Commission for its H share full circulation plan. This includes converting 48.3 million previously unlisted shares into H shares for trading on the Hong Kong Stock Exchange, enhancing liquidity and broadening its investor base. The approval is valid for 12 months from March 26, 2026. Analysts rate the stock as a Buy with a target price of HK$6.00. The company specializes in medical polymer products and is listed on the Hong Kong Stock Exchange.

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Shandong Weigao Wins CSRC Approval for H Share Full Circulation Plan

06090

02632

01126

03887

01798

01440

02650

02630

02729

BUTONG GROUP(06090) fell 21.1%, with a trading turnover 43.6 Million HKD, and a year-to-date fell 49%. NEW VISION CO(02632) fell 18.97%, with a trading turnover 20.5 Million HKD, and a year-to-date rose 6.3%. WEIGAO GROUP(01066) fell 17.47%, with a trading turnover 367.4 Million HKD, and a year-to-date fell 24.7%.

Top Gainers&Losers

BUTONG GROUP

NEW VISION CO

DREAM INT'L

HASHKEY HLDGS

DATANG RENEW

STAR SHINE HLDG

ZHIDA TECH

VIGONVITA-B

GALAXIS TECH

Top 10 HK Stock Losers (3.30)

Citi has lowered the target price for WEIGAO GROUP to HKD 6, expecting revenue growth of 2.3% to RMB 13.389 billion in 2025, and a net profit decline of 22% to RMB 1.612 billion, which is below expectations. Management has committed to maintaining a 50% payout ratio, with revenue growth expected to increase by 4% to 8% in 2026. Citi has revised down its revenue forecasts for this year and next by 5.2% and 8.1%, respectively, and lowered its earnings per share forecasts by 36% and 37%

AASTOCKS

Citi lowered the target price for Shandong Weigao to 6 yuan, expecting a revenue growth of 4% to 8% this year

WEIGAO GROUP announced a related transaction to acquire an industrial land located in Weihai City, Shandong Province, adjacent to the group's production base, for a cash consideration of RMB 39.71 million, which will be paid using internal resources

WEIGAO GROUP spent RMB 39.71 million to acquire industrial land in Weihai

688161

Shandong Weigao Group Medical Polymer Co, a Hong Kong-listed medical device maker, announced that its orthopaedic subsidiary has disclosed information on the Shanghai Stock Exchange, complying with listing rules in both PRC and Hong Kong. This move emphasizes the company's commitment to regulatory transparency and consistent communication with investors across markets. The latest analyst rating for the stock (HK:1066) is a Hold with a price target of HK$5.50, and the company has a market cap of HK$20.08B.

Wego Ortho

Weigao Group Flags Orthopaedic Unit Disclosure on Shanghai Exchange

Shandong Weigao Medical Polymer Co. (OTCMKTS:SHWGF) experienced a significant increase in short interest in March, rising 97.6% to 1,990,267 shares from 1,007,422 shares in February. Currently, 0.0% of the company's stock is sold short, with an infinite short-interest ratio due to zero average daily trading volume. The stock opened at $0.73, with a one-year low of $0.67 and a high of $0.73. The company specializes in single-use medical devices and is based in Weihai, Shandong Province.

Shandong Weigao Medical Polymer Co. (OTCMKTS:SHWGF) Short Interest Up 97.6% in March

WEIGAO GROUP(01066.HK)

M Stanley Cuts WEIGAO GROUP TP to HKD5.2, Lowers EPS Forecasts